Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy

被引:42
|
作者
George, L
Bladou, F
Bardou, VJ
Gravis, G
Tallet, A
Alzieu, C
Serment, G
Salem, N
机构
[1] Hop Salvator, Dept Urol, F-13274 Marseille 9, France
[2] Inst J Paoli I Calmettes, Dept Radiotherapy, F-13009 Marseille, France
[3] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France
[4] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
关键词
D O I
10.1016/j.urology.2004.04.088
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To describe the outcome of patients with muscle-invasive bladder carcinoma treated with multimodality therapy in our institution from 1993 to 2002. Methods. The charts of 60 patients with Stage T2-T4N0-N1M0 treated with transurethral resection of bladder tumor followed by a chemoradiotherapy combination were retrospectively reviewed. Of the 60 patients, 22 had received neoadjuvant chemotherapy (methotrexate, cisplatin, and vinblastine or methotrexate, adriamycin, cisplatin, and vinblastine) followed by concomitant chemoradiotherapy (weekly cisplatin/carboplatin or a cisplatin and 5-fluorouracil combination), and 38 had received concomitant chemoradiotherapy alone. Radiotherapy delivered a median dose of 45 Gy to the pelvis and 65 Gy to the bladder in a once-daily or twice-daily fractionation scheme. Follow-up evaluations included cystoscopy with biopsies at regular intervals. Salvage cystectomy was recommended in the case of local persistent tumor or bladder relapse. Results. The median follow-up was 48.5 months (range 10 to 126). Of the 22 patients who received neoadjuvant chemotherapy, 18 (82%) had received two or more cycles; 51 (85%) of the 60 patients received the concomitant chemotherapy as planned. Radiotherapy was completed in 56 patients. Twenty-eight patients developed relapse either locally (14 did not achieve a complete local response after chemoradiotherapy and 6 had true local relapse during follow-up) or at distant sites. The actuarial 5-year disease-specific survival and freedom from local and distant relapse rate was 54% and 42%, respectively. The actuarial local control rate with an intact bladder was 56% at 5 years. When stratified according to stage and grade, patients with Stage T2-T3, grade 2 tumors had a statistically significantly better chance of remaining relapse free than did the others (P = 0.045). Salvage cystectomy (n = 11) for isolated local failure in this population achieved limited results. Conclusions. Transurethral resection of bladder tumor with this chemoradiotherapy combination achieved satisfactory results in this unfavorable Population with invasive bladder carcinoma.
引用
收藏
页码:488 / 493
页数:6
相关论文
共 50 条
  • [41] Is there a role for surgery in the multimodality treatment of locally advanced pancreatic carcinoma?
    Meyers, M
    Hoffman, J
    Ross, E
    Meropol, N
    Freedman, G
    Brown, T
    Eisenberg, B
    [J]. GASTROENTEROLOGY, 2002, 123 (01) : 39 - 40
  • [42] Clinical Outcome and Prognostic Factors in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Followed by Surgery and Postmastectomy Radiation Therapy
    Nakajima, N.
    Oguchi, M.
    Kumai, Y.
    Yoshida, M.
    Iwase, T.
    Ito, Y.
    Akiyama, F.
    Ohno, S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E22 - E22
  • [43] CHEMORADIOTHERAPY IN LOCALLY ADVANCED BLADDER-CARCINOMA
    LOEHRER, PJ
    [J]. SEMINARS IN ONCOLOGY, 1992, 19 (04) : 92 - 95
  • [44] Clinical outcome of patients with locally advanced head and neck cancer treated by induction chemotherapy followed by chemoradiation
    Broemme, J.
    Schmuecking, M.
    Arnold, A.
    Vock, J.
    Klaeser, B.
    Zbaeren, P.
    Rauch, D.
    Krause, T.
    Aebersold, D. M.
    Geretschlaeger, A.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 96 - 96
  • [45] CLINICAL OUTCOME OF PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER TREATED BY INDUCTION CHEMOTHERAPY FOLLOWED BY CHEMORADIATION
    Broemme, J.
    Arnold, A.
    Krueger, K.
    Geretschlaeger, A.
    Klaeser, B.
    Zbaeren, P.
    Vock, J.
    Schmuecking, M.
    Aebersold, D. M.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (08) : 535 - 535
  • [46] CLINICAL OUTCOME OF PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER TREATED BY INDUCTION CHEMOTHERAPY FOLLOWED BY CHEMORADIATION
    Bromme, J. O.
    Vock, J.
    Arnold, A.
    Geretschlager, A.
    Klaeser, B.
    Zbaren, P.
    Rauch, D.
    Krause, T.
    Aebersold, D. M.
    Schmuecking, M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S320 - S321
  • [47] Distant outcome of patients with locally advanced unresectable and metastatic esophageal cancer after multimodality treatment
    Gruia, I.
    Trifanescu, O.
    Bara, M.
    Moldoveanu, V.
    Anghel, R.
    Toma, R.
    Gales, L.
    Constantinoiu, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 23 - 23
  • [48] National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer
    Sada, Yvonne H.
    Smaglo, Brandon G.
    Cao, Hop S. Tran
    Mok, Henry
    Musher, Benjamin L.
    Massarweh, Nader N.
    [J]. JOURNAL OF SURGICAL RESEARCH, 2019, 237 : 41 - 49
  • [49] Preoperative multimodality therapy for locally advanced rectal cancer in Pakistan
    Jamshed, A.
    Shah, A. A.
    Yousaf, A.
    Saeed, A.
    Rafay, A.
    Khan, Y.
    ud Din, N.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S238 - S239
  • [50] Response prediction in the multimodality therapy of locally advanced rectal cancer
    Vallboehmer, Daniel
    Krieg, Andreas
    Stoecklein, Nikolas H.
    Knoefel, Wolfram T.
    [J]. COLORECTAL CANCER, 2012, 1 (01) : 49 - 55